IMV to Host a Webcast to Spotlight its Immune-Educating DPX® Platform

Date:


Article content material

Occasion will characteristic Michael Kalos, Ph.D., member of IMV’s Board of Administrators and internationally acknowledged skilled in T cell remedy and immunotherapy

Reside webinar on Thursday, February twenty fourth @ 8amET, registration particulars under

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass. — IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage firm growing a portfolio of immune-educating therapies based mostly on its novel DPX platform to deal with strong and hematological cancers, at the moment introduced that it’s internet hosting a Analysis and Improvement Day” by way of webcast on Thursday, February 24, 2022 at 8:00am Japanese Time to focus on the differentiating options of its patented DPX supply platform.

Commercial

Article content material

IMV’s DPX expertise is a supply platform that may incorporate a variety of bioactive molecules to provide focused, long-lasting immune responses enabled by numerous formulated parts. This versatile, immune-educating expertise is being developed for utility in a wide range of therapeutic areas (e.g., oncology, infectious illness) the place technology of a target-specific immune response is predicted to mitigate illness.

The webcast will characteristic a presentation by Michael Kalos, Ph.D., Key Opinion Chief (KOL) and member of IMV’s board of administrators, who will focus on the potential of IMV’s DPX supply platform in addressing unmet medical wants within the present and future oncology panorama.

The IMV crew will describe the DPX supply platform expertise and its differentiated immune-educating capabilities, highlighting key benefits demonstrated in each medical and preclinical research together with its favorable security profile. IMV administration will even present an replace on the Firm’s medical packages and focus on key anticipated milestones in 2022. A dwell query and reply session will comply with.

To register for the Analysis and Improvement Day, please click on right here.

Michael Kalos, Ph.D. is an internationally acknowledged skilled in T cell remedy and immunotherapy and brings over 25 years of expertise and experience in cell remedy, oncology vaccines, and immune-oncology. Dr. Kalos has held govt and R&D management positions in biopharma at Arsenal Bio, Janssen, and Eli Lilly. Previous to his profession within the biopharmaceutical sector, Dr. Kalos spent 10 years in academia, the place he targeted on the event of built-in translational biomarker packages to help the event of cell remedy and immunotherapy packages. The laboratory he based and directed on the College of Pennsylvania performed a key position within the success of the medical cell remedy program at Penn, together with the event of the CTL019 program, which was licensed to Novartis and led to Kymriah, the primary authorized CART cell remedy product.

Dr. Kalos obtained his Ph.D. from the College of Minnesota and accomplished post-doctoral coaching within the laboratory of Phil Greenberg on the Fred Hutchinson Most cancers Analysis Heart. He has co-authored over 85 peer-reviewed manuscripts, together with a number of extremely cited articles in high-impact journals which have helped outline the house of CAR- and TCR- based mostly T cell remedy, in addition to e book chapters within the area of most cancers immunotherapy. He additionally has over 26 issued patents within the fields of cell remedy, immunotherapy, and vaccines. Dr. Kalos now actively serves in an advisory capability for a lot of biopharmaceutical firms in addition to worldwide immunotherapy consortia and organizations.

Commercial

Article content material

About IMV

IMV Inc. is a clinical-stage immuno-oncology firm advancing a portfolio of therapies based mostly on the Firm’s immune-educating platform: the DPX™ expertise. By a differentiated mechanism of motion, the DPX platform delivers instruction to the immune system to generate a selected, sturdy, and protracted immune response. IMV’s lead candidate, maveropepimut-S (MVP-S), delivers antigenic peptides of survivin, a well-recognized most cancers antigen generally overexpressed in superior cancers. MVP-S therapy has been effectively tolerated and has demonstrated outlined medical profit in a number of most cancers indications in addition to the activation of a focused and sustained, survivin-specific anti-tumor immune response. MVP-S is at present being evaluated in medical trials for hematologic and strong cancers, together with Diffuse Giant B Cell Lymphoma (DLBCL) in addition to ovarian, bladder and breast cancers. IMV can be growing a second immunotherapy leveraging the DPX immune supply platform, DPX-SurMAGE. This dual-targeted immunotherapy combines antigenic peptides for each the survivin and MAGE-A9 most cancers proteins to elicit immune responses to those two distinct most cancers antigens concurrently. A Part 1 medical trial in bladder most cancers was initiated in early 2022. For extra info, go to www.imv-inc.com and join with us on Twitter and LinkedIn.

IMV Ahead-Trying Statements

This press launch accommodates forward-looking info below relevant securities regulation. All info that addresses actions or developments that we count on to happen sooner or later is forward-looking info. Ahead-looking statements use such phrase as “will”, “might”, “potential”, “imagine”, “count on”, “proceed”, “anticipate” and different comparable terminology. Ahead-looking statements are based mostly on the estimates and opinions of administration on the date the statements are made. Within the press launch, such forward-looking statements embrace, however will not be restricted to, statements concerning the potential affect of the VITALIZE examine and the anticipated date information from such examine is out there, the Firm’s capacity to advance its growth technique, in addition to the prospects, for its lead immunotherapy and its different pipeline of immunotherapy candidates. Nevertheless, they shouldn’t be considered a illustration that any of the plans will probably be achieved. Precise outcomes might differ materially from these set forth on this press launch resulting from dangers affecting the Firm, together with entry to capital, the profitable design and completion of medical trials and the well timed receipt of all regulatory approvals to start, after which proceed, medical research and trials and the receipt of all regulatory approvals to commercialize its merchandise. IMV Inc. assumes no accountability to replace forward-looking statements on this press launch besides as required by regulation. These forward-looking statements contain identified and unknown dangers and uncertainties, and people dangers and uncertainties embrace, however will not be restricted to, the flexibility to entry capital, the profitable and, typically, the well timed completion of medical trials and research and the receipt of all regulatory approvals in addition to different dangers detailed sometimes in our ongoing quarterly filings and annual info kind. Traders are cautioned to not depend on these forward-looking statements and are inspired to learn IMV’s steady disclosure paperwork, together with its present annual info kind, in addition to its audited annual consolidated monetary statements which can be found on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar

Commercial

Article content material

View supply model on businesswire.com: https://www.businesswire.com/information/house/20220217005143/en/

logo

Contacts

Investor Relations
Pleasure Bessenger, Senior Vice President, Investor Relations and Company Technique
O: (902) 492.1819 ext: 2009
E: jbessenger@imv-inc.com

Marc Jasmin, Senior Director, Investor Relations, IMV Inc.
O: (902) 492-1819 ext : 1042
M: (514) 617-9481 E: mjasmin@imv-inc.com

Irina Koffler, Managing Director, LifeSci Advisors
O: (646) 970-4681
M: (917) 734-7387
E: ikoffler@lifesciadvisors.com

Media
Delphine Davan, Senior Director, Communications, IMV Inc.

M: (514) 968 1046
E: ddavan@imv-inc.com

Madeline Joanis, Senior Account Govt, LifeSci Communications
M: (603) 479 5267
E: mjoanis@lifescicomms.com

#distro

Commercial

Feedback

Postmedia is dedicated to sustaining a full of life however civil discussion board for dialogue and encourage all readers to share their views on our articles. Feedback might take as much as an hour for moderation earlier than showing on the positioning. We ask you to maintain your feedback related and respectful. We’ve got enabled electronic mail notifications—you’ll now obtain an electronic mail in the event you obtain a reply to your remark, there’s an replace to a remark thread you comply with or if a person you comply with feedback. Go to our Neighborhood Tips for extra info and particulars on the way to modify your electronic mail settings.



LEAVE A REPLY

Please enter your comment!
Please enter your name here

Share post:

Popular

More like this
Related

Monitoring adoption a yr later By Cointelegraph

El Salvador's Bitcoin determination: Monitoring adoption a yr...

Plains All American Pipeline: Potential 10%+ Yield (NASDAQ:PAA)

Conclusion It stays unsure whether or not...

What’s (Not) Taking place within the Coronavirus Disaster?

The massive information this previous week has been...

You Want This A lot to Reside Off Dividends

Dividend shares and dividend ETFs can present diversification...